【文章名】Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
Evaluation of the Antiviral Response to Zanamivir Administered Intravenously for Treatment of Critically Ill Patients With Pandemic Influenza A (H1N1) Infection
作者
Fraaij, PLA; van der Vries, E; Beersma, MFC; Riezebos-Brilman, A; Niesters, HGM; van der Eijk, AA; de Jong, MD; Miranda, DR; Horrevorts, AM; Ridwan, BU; Wolfhagen, MJHM; Houmes, RJ; van Dissel, JT; Fouchier, RAM; Kroes, ACM; Koopmans, MP; Osterhaus, ADME; Boucher, CAB
[摘要]：A retrospective nationwide study on the use of intravenous (IV) zanamivir in patients receiving intensive care who were pretreated with oseltamivir in the Netherlands was performed. In 6 of 13 patients with a sustained reduction of the viral load, the median time to start IV zanamivir was 9 days (range, 4-11 days) compared with 14 days (range, 6-21 days) in 7 patients without viral load reduction (P = .052). Viral load response did not influence mortality. We conclude that IV zanamivir as late add-on therapy has limited effectiveness. The effect of an immediate start with IV zanamivir monotherapy or in combination with other drugs need to be evaluated.
